Last reviewed 2026-05-13 · How we verify

arimidex dummy

Arimidex is an aromatase inhibitor that blocks the enzyme responsible for converting androgens to estrogens.

Arimidex is an aromatase inhibitor that blocks the enzyme responsible for converting androgens to estrogens. Used for Treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy, Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women following surgery.

At a glance

Mechanism of action

By inhibiting this enzyme, Arimidex reduces estrogen levels in the body, which can help slow or stop the growth of hormone receptor-positive breast cancer cells. This mechanism is particularly effective in postmenopausal women, as their bodies produce less estrogen naturally.

Approved indications

• Treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy
• Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women following surgery

Common side effects

• Hot flashes
• Musculoskeletal pain
• Arthralgia
• Fatigue
• Nausea

Key clinical trials

• A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer. (PHASE3)
• Bay98-7196, Dose Finding / POC Study (PHASE2)
• Faslodex Advanced Breast Cancer Local Chinese Study (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• arimidex dummy CI brief — competitive landscape report
• arimidex dummy updates RSS · CI watch RSS
• AstraZeneca portfolio CI